466
2020년 제 71차 대한내과학회 추계학술대회
￭S-423 ￭ Prevalence and clinical characteristics of DPN in type 2 DM:
Results from a NHIS DB, 2012-2017
부천세종병원 내과 김봉천, 김종화, 정수진
Background/Aims: To determine the prevalence and clinical characteristics of diabetic peripheral neuropathy in patients with type 2 diabetes in Korea.
Methods: From the target population a representative sample cohort of 1,422,492 participants was randomly selected, comprising 3%
of the total eligible Korean population in 2012, and followed until 2017. Strata were constructed by age group, sex, eligibility status and income level. During the follow-up period, the cohort was refreshed annually by adding a representative sample of newborns. Data source: NHIS: National Health Insurance Service. Definition of diabetic peripheral neuropathy (DPN): i) Diagnosed with DPN (ICD-10 codes E10.4, E11.4, E12.4, E13.4, and E14.4). ii) Diagnosed with DPN (ICD-codes G59.0, G63.2, and G99.0). iii) Receiving a prescription for DPN drugs and DM drugs
Results: From 2012 to 2017, the prevalence of DPN in diabetic patients was 27.0%- 24.0%. DPN medication was administered in 59.3%
to 57.8% of DPN patients. Drug therapy was prescribed for up to 82% mono therapy, dual combination treatment for up to 15%, and triple combination treatment for up to 3%. Prescribed medications for DPN from 2012 to 2017 were α-lipoic acid (60.8% to 58.8%), anti¬convulsant drugs (26.1% to 27.4%), tricyclic antidepressants (10.4% to 8.1%), serotonin-norepinephrine reuptake inhibitors (1.6%
to 3.4%), γ-linoleic acid (2.1% to 2.3%). Persistency for pharmacological treatment of DPN was 34.2%- 35.7%, and the rate of persistency was increasing over time.
Conclusions: The prevalence of DPN patients is about a quarter of those with diabetes, and medication is about 60 percent, and most medications are administered with mono therapy.
